Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Palliative Care × Dermatologic × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5 Genitourinary 4 Tumor-Agnostic 3 Thoracic 3 Other hematologic neoplasm 3 Other solid neoplasm 2 Lymphoid 2 Head & Neck 2 Breast 2 Sarcoma 1 Gynecologic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 62 Nivolumab 57 Ipilimumab 29 Specimen Handling 26 Magnetic Resonance Spectroscopy 24 Cyclophosphamide 19 Biopsy 19 cemiplimab 15 fludarabine 14 trametinib 13 relatlimab 12 CTLA-4 Antigen 10 Interleukin-2 9 binimetinib 8 aldesleukin 8 Opdualag 8 fludarabine phosphate 7 dabrafenib 7 Radiosurgery 7 encorafenib 6 avelumab 6 atezolizumab 6 Temozolomide 6 Radiotherapy 5 Introns 5 Immunoglobulin G 5 Aminolevulinic Acid 5 cobimetinib 4 Standard of Care 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02645149 2026-02-27

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡